Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q02108

UPID:
GCYA1_HUMAN

ALTERNATIVE NAMES:
Guanylate cyclase soluble subunit alpha-3; Soluble guanylate cyclase large subunit

ALTERNATIVE UPACC:
Q02108; D3DP19; D6RDW3; O43843; Q8TAH3

BACKGROUND:
The Guanylate cyclase soluble subunit alpha-1, with alternative names such as Guanylate cyclase soluble subunit alpha-3 and Soluble guanylate cyclase large subunit, is integral to the conversion of GTP to cGMP, a critical messenger in cellular communication. This process is essential for maintaining cardiovascular function, neural transmission, and smooth muscle relaxation.

THERAPEUTIC SIGNIFICANCE:
Given its association with Moyamoya disease 6, a condition marked by severe cerebral angiopathy and early-onset achalasia, the study of Guanylate cyclase soluble subunit alpha-1 offers promising avenues for the development of novel therapeutic interventions aimed at improving outcomes for individuals affected by this and potentially other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.